Clinical Trials Logo

Dyskinesias clinical trials

View clinical trials related to Dyskinesias.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06240624 Recruiting - Clinical trials for Levodopa-induced Dyskinesia in Parkinson's Disease

Dynamic Brain Mapping of the Functional Effects of Levodopa on Multiple Cortex-basal Ganglia Circuits in Parkinson ́s Disease

Dyn-fMRI-PD
Start date: August 15, 2022
Phase:
Study type: Observational

Levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) are involuntary movements caused by long-term treatment with dopaminergic replacement therapy (levodopa). During the cause of PD, most patients develop LID. In this study, the investigators plan to investigate how the cortico-basal-ganglia networks are affected in LID. The investigators will examine PD patients with and without LID as well as healthy age-matched controls using fMRI and PET. During the fMRI experiment, participants will perform a novel go-no task engaging both motor, emotional and reward brain networks. Patients will be scanned before and after intake of levodopa to study the dynamic effects of dopaminergic therapy. Furthermore, a dopamine transporter PET will be acquired to study the dopaminergic degeneration of the patients with PD.

NCT ID: NCT06239454 Recruiting - Parkinson's Disease Clinical Trials

Interleaving Stimulation Improves Dyskinesia in Parkinson's Disease

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This study is designed as a prospective, randomized, double-blind, controlled study to assess putative differences in the effect of interleaving stimulation and empirical stimulation with regards to post-operation dyskinesia control. The primary objective is to assess putative differences in the effect of interleaving stimulation and empirical stimulation with regards to dyskinesia control.

NCT ID: NCT06216054 Recruiting - Huntington Disease Clinical Trials

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Start date: December 23, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.

NCT ID: NCT06202391 Recruiting - Scapular Dyskinesis Clinical Trials

Autogenic Inhibition Versus Reciprocal Inhibition Muscle Energy Techniques Effect on Swimming Performance on Swimmers With Scapular Dyskinesis

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

Swimming can cause shoulder pain due to scapular dyskinesis. Proper scapula movement is necessary for efficient swimming strokes and to avoid injury. Studying the effects of autogenic and reciprocal inhibition muscle energy techniques on swimmers with scapular dyskinesis can lead to effective interventions and reduce shoulder injuries

NCT ID: NCT06172374 Recruiting - Clinical trials for Primary Ciliary Dyskinesia

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

Start date: August 31, 2023
Phase:
Study type: Observational

Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

NCT ID: NCT06131086 Recruiting - Scapular Dyskinesis Clinical Trials

Effect of Scapular Stabilization Excercise With Pectoralis Minor Stretching in Ballers Having Scapular Dyskinesia

Start date: October 20, 2023
Phase: N/A
Study type: Interventional

The study is randomized and single -blinded. Ethical approval is taken from ethical committee of Riphah International university Lahore. participant selected through non probability convenience sampling technique on 26 fast bowlers which further players were randomly divided into two groups, group A (Experimental group) and group B (Control group), having 13 players in each group. Scapular stabilization exercises along with pectoralis minor stretching were administered in group A whereas generalized shoulder exercises along with self-stretching of shoulder muscles were performed in group B.

NCT ID: NCT06110000 Recruiting - Adhesive Capsulitis Clinical Trials

Pragmatic Set of Interventions Versus Scapular Strengthening Exercises on Scapular Dyskinesia in Adhesive Capsulitis

Start date: May 8, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to determine the Effects of pragmatic set of interventions versus scapular strengthening exercises on scapular dyskinesia in adhesive capsulitis.

NCT ID: NCT06011408 Recruiting - Tardive Dyskinesia Clinical Trials

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

Start date: May 30, 2023
Phase: N/A
Study type: Interventional

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.

NCT ID: NCT05951478 Recruiting - Clinical trials for Primary Ciliary Dyskinesia

DCP (RaDiCo Cohort) (RaDiCo-DCP)

DCP
Start date: May 2, 2017
Phase:
Study type: Observational

Primary Ciliary Dyskinesias (PCD) are rare, autosomal recessive respiratory diseases, due to a defect in mucociliary clearance linked to abnormalities in the structure and/or function of the cilia. The variety of ciliary abnormalities identified reflects the genetic heterogeneity of PCDs. The thirty or so genes currently implicated explain the pathology in about half of the patients. PCDs are characterized by recurrent infections of the upper (rhinosinusitis) and lower (bronchitis) airways, beginning in early childhood and progressing respectively to nasal polyposis and bronchial dilatation. In half of the cases, there is a lateralization defect of the organs (situs inversus) corresponding to Kartagener's syndrome. There is more frequent infertility in men (immobility of spermatozoa) than in women (miscarriages and tubal pregnancies). About a third of patients progress to respiratory failure. The identification of predictive factors of severity, specific to PCDs, would improve patient care. It is also important to assess the quality of life of patients with PCD, particularly at the ENT level. Data from prevalent patients are currently integrated into three separate and complementary databases: the "e-RespiRare" database, the "DCP Cils" database and the "DCP genes" database. The first step is therefore to constitute the RaDiCo-DCP database which will include data from prevalent and incident patients whose diagnosis of PCD is certain. The cohort aims to improve the routine care of PCD patients, in particular by highlighting predictive factors of severity, allowing early and personalized care, to assess the social impact (quality of life) and medical conditions of ENT impairment, as well as adult infertility, to finely characterize the ciliary phenotype. The study also aims to search for new DCP genes and to allow genotype/phenotype correlation studies.

NCT ID: NCT05932316 Recruiting - Cystic Fibrosis Clinical Trials

Evaluating Bronchodilator Response in Patients With Bronchiectasis

Start date: May 20, 2023
Phase: N/A
Study type: Interventional

Although patients with bronchiectasis tend to have non reversible obstructive patterns on pulmonary function tests (PFTs), reversible obstruction is not uncommon. While bronchodilator response (BDR) is a main characteristic of asthma, the pathophysiology causing this phenomenon in bronchiectasis patients is less clear. The goal of this clinical trial is to assess BDR in patients with bronchiectasis. The main aims of this study: 1. To evaluate the role of bronchodilators in BDR testing of patients with bronchiectasis. 2. Characterize and compare BDR between different subgroups of patients with bronchiectasis, and compared to patients without bronchiectasis (healthy controls). 3. Identify demographics and other clinical variables associated with positive BDR Participants will be taking a series of three spirometry tests: After the first spirometry testing, patients will be randomly assigned to receive bronchodilators as per bronchodilator response protocol (Salbutamol, 100 mcg, 4 puffs via spacer) or four puffs of placebo. After a waiting time of 15 minutes, spirometry will be repeated. Following the second spirometry testing those who received salbutamol will now receive placebo and those receiving placebo will receive Salbutamol. After a second period of 15 minutes, a third series of spirometry will be recorded.